The structure of 5-azacytidine

Find information on thousands of medical conditions and prescription drugs.

Azacitidine

5-azacytidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Cells in the presence of 5-azacytidine incorporate it into DNA during transcription and RNA during translation. The incorporation of 5-azacytidine into DNA or RNA inhibits methyltransferase thereby causing demethylation in that sequence, affecting the way that cell regulation proteins are able to bind to the DNA/RNA substrate.

5-azacytidine is mainly used in the treatment of myelodysplastic syndrome. It is marketed as Vidaza.

A

Acetylcholine chloride

Acetyldigitoxin

Alvircept sudotox

Aminocaproic acid

Aminoglutethimide

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Read more at Wikipedia.org

• [List your site here Free!]


		Gale Encyclopedia of Cancer : Azacitidine $1.50			Azacitidine: A novel drug for myelodysplastic syndrome.(Molecules of the Millennium) : An article from: Indian Journal of Pharmacology $5.95


	Azacitidine: A novel drug for myelodysplastic syndrome Byline: K. Mahesh Kumar Myelodysplastic syndrome (MDS)is a group of diseases showing different outcomes depending on its clinical presentations, which ... From Indian Journal of Pharmacology, 11/1/05 by K. Mahesh Kumar

	Azacitidine Definition Azacitidine, is an antineoplastic (antitumor) agent that acts by interfering with the growth of cells. Purpose Azacitidine is ... From Gale Encyclopedia of Cancer, by Ph.D. Michael Zuck

	MethylGene Initiates Phase I/II Clinical Trial with MGCD0103 and Azacitidine in Patients with MDS and AML MONTREAL -- MethylGene Inc. (TSX:MYG) a biopharmaceutical company, today announced that it has initiated the first of several Phase I/II clinical trials which will evaluate the combination therap From Business Wire, 11/14/05

	Medsafe Byline: J. Singh www.medsafe.gov.nz The World Health Organization (WHO) has popularised the approach that access to medicines relies on four integral ... From Indian Journal of Pharmacology, 11/1/05 by J. Singh

	Book Review Byline: N. Ananthakrishnan National workshops on good clinical practices and regulatory requirements for clinical trails in India, Training Manual ... From Indian Journal of Pharmacology, 11/1/05 by N. Ananthakrishnan

	New drug for bone marrow disease The FDA has approved the first effective treatment for people with a collection of disorders called myelodysplastic syndrome (MDS), in which bone marrow ... From FDA Consumer, 7/1/04 by

	Marrow drug gets FDA OK Marrow drug gets FDA OK Associated Press Monday, May 24, 2004 Washington -- The government has approved sale of the first drug to treat a bone marrow disease that can lead to leukemia. From Milwaukee Journal Sentinel, The, 5/24/04

	Clinical Data on Vidaza® in Higher-Risk MDS, AML and Other Hematological Malignancies to be Presented at the American Society of Hematology Annual BOULDER, Colo., Dec. 8 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today that data from several Vidaza(R) studies will be presented at ... From PR Newswire, 12/8/05

Home

Contact

Resources

ebay